Does 17β-estradiol play a role in SLE-associated atherosclerosis?

Atherosclerosis is the buildup of plaque on artery walls, causing stenosis which can eventually lead to clinically apparent cardiovascular disease. Find the latest research on atherosclerosis disease progression here.

Does 17β-estradiol play a role in SLE-associated atherosclerosis?

Abstract

References

Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study

Estrogen up-regulates Bcl-2 and blocks tolerance induction of naive B cells

Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus

Inflammation in atherosclerosis

Diabetes undermines estrogen control of inducible nitric oxide synthase function in rat aortic smooth muscle cells through overexpression of estrogen receptor-beta

Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus

Immune dysregulation accelerates atherosclerosis and modulates plaque composition in systemic lupus erythematosus.

Estrogen receptor signaling and its relationship to cytokines in systemic lupus erythematosus.

Accelerated atherosclerosis in patients with SLE--mechanisms and management.

17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice

Citations

Dual antiplatelet therapy for heart disease

Related Concepts

Related Feeds

Atherosclerosis Disease Progression

Related Papers

The lupus anticoagulant is a risk factor for myocardial infarction (but not atherosclerosis): Hopkins Lupus Cohort

Systemic lupus erythematosus and accelerated atherosclerosis

17-β Estradiol reduces atherosclerosis without exacerbating lupus in ovariectomized systemic lupus erythematosus-susceptible LDLr(-/-) mice

Heart valve calcification in young patients with systemic lupus erythematosus: a window to premature atherosclerotic vascular morbidity and a risk factor for all-cause mortality

Use of a strategy based on calculated risk scores in managing cardiovascular risk factors in a large British cohort of patients with systemic lupus erythematosus